

Indoco's Net Revenues Up by 16 % Q-o-Q

Receives ANDA approval for Allopurinol tablets

Mumbai, July 29, 2016: Indoco Remedies posted total revenues of ₹ 252.7 crores for the first quarter of Apr 16-June16, up by 15.8 %, as against ₹ 218.2 crores for the same period last year. Profit After Tax (PAT) for the quarter was at ₹ 19.8 crores compared to ₹ 20.8 crores for the corresponding quarter last year.

The company has received the USFDA approval for its Abbreviated New Drug Application (ANDA) for Allopurinol 100 mg and 300 mg tablets. Allopurinol is indicated for treatment of Gout. The market size of this product in the US is \$169 million.

Commenting on this development, Aditi Panandikar, Managing Director, Indoco Remedies Ltd, said, "Double digit growth in Domestic formulation business is encouraging and the numbers of the emerging markets for the quarter are also impressive. The Company is fully integrated to manufacture Allopurinol (API & tablets) and will be soon launching this product in the US market."

The Company's domestic formulation business introduced 14 new products, six in Anti-diabetic category, two each in Gynaec and Stomatologicals, one each in Anti-infective, Gastro intestinal, Ophthalmic and Urological respectively.

For the quarter ended June'16, the financials are as under:

Particulars	(₹ in Crores)	
	Apr'16 – June'16	Apr'15 – June'15
Net Revenue	252.7	218.2
EBIDTA	41.8	42.7
Profit After Tax	19.8	20.8
EPS (Face value ₹ 2/-) (Not annualized)	2.15	2.26

About Indoco Remedies Limited:

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries. Indoco, a USD 149 million Company, employs over 5500 people including 300 skilled scientists.

The Company has 8 manufacturing facilities, 5 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by USFDA, UK-MHRA, TGA-Australia, MCC-South Africa, etc. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 60 million prescriptions annually from around 2,00,000 doctors in India. Indoco has 10 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Respiratory, Anti-Infective, Dental Care, Pain

Management, Gastro-intestinal, Ophthalmic, Cardiovascular, Anti-Diabetics, Anti-Obesity, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Oxipod, Cital, ATM, Cloben-G, Sensoform, Sensodent-KF, Karvol Plus, Glychek, Tuspel Plus, etc. On the international front, Indoco has tie-ups with large generic companies like Watson (Actavis) – USA and ASPEN-South Africa.

For more details on Indoco, you may visit www.indoco.com

For Media Inquiries Please Contact:

Kailash Rajwadkar

Mobile: 9869333999 / 9869111687

E-mail: kailash.rajwadkar@gmail.com

Vilas V. Nagare

Mobile: 9820215745

E-mail: vilasn@indoco.com